Contributor Disclosures for Endemic Syphilis

Role Name Disclosure Details Author  Hassan Galadari, MD, MBBS, Resident, Department of Dermatology, Boston Medical Center, Tufts-New England Medical Center, Nothing to disclose Details Coauthor  Ibrahim Galadari, MD, MB, BCh, MSc, Chair of Dermatology and Venereology, Associate Professor, Department of Dermatology, Al Ain Hospital, United Arab Emirates University Nothing to disclose Details Medical Editor  Craig A Elmets, MD, Director of Dermatology, Departments of Dermatology, Pathology, and Environmental Health Sciences; Professor, The Kirklin Clinic, University of Alabama at Birmingham Palomar Medical Technologies Merck Tronox Amgen Astellas Massachusetts Medical Society Details Pharmacy Editor  Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center Nothing to disclose Details Managing Editor  Paul Krusinski, MD, Director of Dermatology, Professor, Department of Internal Medicine, Fletcher Allen Health Care, University of Vermont Nothing to disclose Details CME Editor  Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University Nothing to disclose Details Chief Editor  Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center Nothing to disclose Details CONTRIBUTOR DISCLOSURE FORM Contributor Name: Hassan Galadari  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Ibrahim Galadari, Coauthor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Craig A Elmets  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Palomar Medical Technologies Stock None   Merck Consulting fee Independent contractor   Tronox Consulting fee Independent contractor   Amgen Consulting fee Review panel membership   Astellas Consulting fee Review panel membership   Massachusetts Medical Society Salary Employment   Off label or investigational use of medication Dimericine for prevention of skin cancer in renal transplant recipients. Efalizumab in plaque psoriasis who have had an inadequate response to an anti-TNF agent. Rituximab for ocular cicatricial pemphigoid. HuMax-CD4 in patients with mycosis fungoides. Long term safety of alefacept. CONTRIBUTOR DISCLOSURE FORM Contributor Name: Michael J Wells  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Paul Krusinski, Managing Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Catherine Quirk  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Dirk M Elston  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication